Keyword: Deciphera Pharmaceuticals
The filing moves Deciphera closer to establishing ripretinib as an option for patients failed by drugs from Bayer, Novartis and Pfizer.
The data sparked a triple-digit surge in Deciphera’s stock price, even though details of the results leave scope to question ripretinib’s prospects.
FDA chief Scott Gottlieb steps down; Gilead loses oncology leader; Deciphera CEO to retire; and DBV loses two executives ahead of peanut drug refile.
Deciphera CEO Michael Taylor is stepping down just as the company is waiting for a key phase 3 readout for its lead drug ripretinib.
Deciphera aims to get ripretinib approved first as a fourth- and second-line treatment for GIST, but is not looking for a first-line approval.
The early-phase data have emboldened Deciphera to expand the trial to include patients with tenosynovial giant cell tumors.
Despite the focus on immuno-oncology right now, Deciphera has data showing there is still plenty to talk about when it comes to kinase inhibitors.
2017 was "good, but not great" for biotech IPOs, yet insider buying was still high at 34%.
Three biotech companies focusing on cancer and eye diseases have collectively raised more than $300 million.
Deciphera Pharmaceuticals will head to ASCO this week with a spring in its step after raising $52 million in a third-round financing.